Well in thank the and to the of the performance you financial our I'm you continuing to performance. in always Eva our with team to members We through sales delivered results here everyone are as at for QX. truly outstanding and rate take X.X% business room saw Team share joining. Executive and with thanks today financial you strong me delighted the we
specialty in in sales growth billion more stellar at still growing Dupixent it's rate €X care a XX%. to Our XX%. nearly and posted has accelerated above than
Our approvals. by is double-digits products and growing disease legacy franchise recent driven
PPH, into speaks travel up. vaccines another organization. business. continues to Consumer and transforming quarter healthcare recovery agile, and about truly the growth volumes sales drive this at delivered on above vaccines speed our and further the In for of consumer assets another is a quarter fast booster growth our which focus business market centric medicines well it Continued moving, strong general were in core in our pay
medicine of markets potential we pace. treated population into know a certainly the The at underpenetrated X starting patients take let's just over worldwide, million at be years within consider approved to we continues Slide this eligible the around patients. this already point. it will launch really XXX,XXX is And have while to Five Dupixent. remarkable grow immense Moving to a launch, of to X, moment
groups we areas from in first from alone let XXX,XXX biologic infancy needs six-year Dupixent a States of the and suffering paradigm we strategic perspectives. aside Dupixent in to youngest dermatitis in a approved medicine thanks in the the and pediatric quarter asthma atopic label the this On mention and me our of This plan, as received X the the and And complete highlight to Europe to approval approvals megabrand area. is esophagitis phase setting adulthood other all achievements of unmet all children to the high as for The added the United of our shift. future get as making from in age close eosinophilic of let’s patients the first depth in here eligible take this Slide such end some medicines breadth U.S. only moment
consecutive eight growth, delivered growth single-digits. sales high have quarters of more We recently to even accelerated
we margin we and company, and the in the the While least had by with sustainable a track is At XXXX. same such is profitability remain drivers growth BOI focus and thanks these as assets efficiencies our time savings this is at a back reinvesting it in reach guidance largely point was winning strong year our on that probably made we achieved a paying committed to are a across clearly making but and it all XX% performance combined improved execution our our above improvements commercial proof our science result decade on to off. as since
was EuroAPI of model. milestone company. included standalone to modernize quest the recent and is major spin our a but implementation unsuccessful deep cultural The the on so are This important structural We of also transformation modernization changes. out a CHC
growth our will LoE remains Dupixent instrumental several meaningful in strategic will driver U.S. last factors of the our the ahead, for our Clearly, of Sanofi the manage execution. the the help XXXX, on increased It and key to number assets. We'll story. in through Aubagio to LoE be Looking decade, with first investment deep in this and productivity our in in group. breakthrough pharma to least amongst stock making class continue expose focus our one generic peer science competition best
fast will making all maturing years. is nirsevimab term, pipeline by achieving Our success next transformative have the and focus the protection for RSV multiple chances starting in a on short In story upcoming we year. launches from we'll
the efanesoctocog to believe patients. treatment strongly revolutionize we hemophilia after alfa have A for potential shortly Following will
Based data, multiple on tolebrutinib, in of clinical of duration compelling and belief launched brain-penetrant the in patients three efficacy remains program Phase tolebrutinib therapy largest to oral unwavering. on XB XXXX treatment currently up our X MS, the years. inhibitor more sclerosis we BTK full are with spectrum Our than to address Phase
of in We back to first us assessing asked new end pivotal by the expect disappointing out that pause next year. our enrollment revisions protocol the impact May. trial It's read the FDA implemented in the without of U.S. the patient
sign Let me Meanwhile, of will of We XXX address the patients written at dozens the program partial revised of world. in the have None June. continue and request into had end additional implementation the the the around the the FDA's May of quarter. countries X information all Phase clinical studies drug point that enrolled protocols this in FDA from liver to the and injury. in the received hold are by a end feedback out any induced for of U.S. of treat the confident
a I and past be accelerating inflammatory of and building Dupixent organization Type examples just productivity as an R&D X, pipeline. leading Slide not development and our significant the we wide innovation. over a few past the made such the over Moving we've a ambition with transformation, at long-term industry by take closer the marked couple few in slide years, to of made immunology of prouder lead X prioritization clear the R&D could look diseases have of range progress the across of let's to shift years. This simply illustrates
Slide to Moving our pipeline. XX, on hemophilia
advocacy pivotal been to presented the was simply where levels is that have chance before. almost had data ISTH seen certainly follow alfa alfa efanesoctocog efanesoctocog this for never you of agree earlier you will month, reaching If the
there in reason, patients alfa be beyond fact more few me will minutes. efanesoctocog view, my the little have this than are came the beyond when upcoming And once today talk apparent Now And engage to had innovative in other treatments a to and chance another or leaders anything that with even for in frequently. about Bill hemophilia at effect, factors opinion less to little future. the monthly key that using a launch truly I ISTH, is
for to from the potential its other program ongoing forward of more based presenting So every let's month. next not look We forget data fitusiran the year, on schedule fitusiran. revised
clock challenge Moving RSV. recombinant speed. you Committee U.S. recently team available to the the in General this remember on been class RSV on essential had to knew immunization infant working U.S. the solution Immunization infants. and around that for protein accepted RSV to COVID-XX make an Advisory is a the the not a people protect greatly or run Slide against results first, the at first as many is protection platform we're role all play the Meeting was study to XX, a to already With in efficacy starting the the approved. extra all was where ACIP infants to Advancing of Yes, XX, Nirsevimab, once needed of recognized pivotal achieving common trials during vaccinated agenda Slide Nirsevimab of hospitalization most on the to Practices of in we but get against not were the we campaigns. built infected time first cause positioned
vaccine of include study of an our a a Why into in underlining concern. beta? strength beta published to and other test because the our us clearly Phase protection Well, the allows However, recently platform. it Omicron variance of cross based and for allowed a for were on number Results to containing across efficacy for a world. science vaccine it broad combinant X variants
Whilst As recombinant said interesting The financial play a a for of this role. not booster meaningful could times, and vaccine the safety. our profile the recombinant authorized, we it many given makes for booster place payers an efficacy solution is a us.
our during Health Global a So XXXX broad is let Health to the made sum unique. the areas of portfolio and To initiative the commitment using picking as well scientific It were very We of month, initiative the to model in simply a is event it dedicated investment first clearly Health to leading at access The many is attendees, in is provide and Global countries Slide as with his a its hand recognized with CSR progress at We close brand. as can and emissions earlier by moving on update society. so now. the and was by to Bill agenda Sanofi presented the of of over see, only you as so at flagship Sanofi our our medicines global Care. and building speed progress by recent that, pandemic, for many our April pace ESG ESG is strategy. and Sanofi the own across and those agencies. up me that launched I'm Global event I Specialty this commercial up, on proud so all XX
